Thomas Tan went from studying medical science and doing research at Oxford and Cambridge to starting a company in Cambridge that built software to automate lab data recording, before moving into venture investing at Sound Bioventures, where he focuses specifically on therapeutics and pushes portfolio companies to think early about pricing and payer evidence in rare disease. He's also drawn to RNA technologies for their potential to lower costs and speed up manufacturing compared to more complex treatments like cell therapy, and this mix of experience has made him a trusted board member for technically demanding therapeutics companies, including Theolytics, Atox Bio, and VarmX.